huXBR1-402
huXBR1-402 (NBE-002 Antibody) is a high-affinity (Kd=5.8 nM) humanized chimeric rabbit/human monoclonal antibody that targets ROR1. huXBR1-402 specifically binds to the Ig/Fz domain epitope of human ROR1, directly inhibits the proliferation of ROR1-positive tumor cells and induces apoptosis of leukemia cells (apoptosis).
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
The antibody-drug conjugate huXBR1-402-G5-PNU inhibits proliferation of ROR1-positive mantle cell lymphoma cells[1].
huXBR1-402 binds to the Ig/Fz domains of human ROR1 with affinity comparable to the parent chimeric antibody XBR1-402[2].
Fully humanized huXBR1-402 specifically binds to human ROR1 expressed on ROR1+ MCL cell lines (JeKo-1, Mino), primary CLL cells[3].
HuXBR1-402 and its antibody-drug conjugate form huXBR1-402-G5-PNU mediate Fc-dependent ADCC and ADCP activity against non-proliferative primary CLL cells, but neither mediates CDC[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
huXBR1-402-G5-PNU (1 mg/kg; i.p.; 3 doses on days 1, 3, and 5 post-randomization; 1 week) increases survival by 3 weeks, stabilizes disease, reduces proliferative leukemic cells, and decreases splenic and peripheral tumor burden in immune competent huROR1-TCL1 CLL mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD-SCID (6-8 week old female, immunodeficient, engrafted with human ROR1+ 697 pre-B cell ALL cells)[3]
-
Dosage:1 mg/kg
-
Administration:i.v.; 2 doses (days 7 and 14 post-engraftment)
-
Result:Prolonged survival significantly compared to isotype control trastuzumab-G5-PNU.
-
Animal Model:C57BL/6 (8 week old, immune competent, engrafted with huROR1-TCL1 spleen-derived leukemic cells)[3]
-
Dosage:1 mg/kg
-
Administration:i.p.; 3 doses (days 1, 3, and 5 post-randomization); 1 week
-
Result:Increased survival by 3 weeks compared to controls.
Stabilized disease for 3 weeks after the last dose.
Decreased numbers of EdU+ proliferating CD19+/CD5+ leukemic cells in spleens.
Significantly reduced splenic mass.
Almost halved peripheral blood tumor cell counts 4 days before euthanasia compared to vehicle and trastuzumab-G5-PNU controls.
Q01973
ROR1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Synonyms
NBE-002 Antibody
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Tigu AB, et al. Therapeutic advances in the targeting of ROR1 in hematological cancers. Cell Death Discov. 2024;10(1):471. Published 2024 Nov 17. [Content Brief]
[2]. Peng H, et al. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Antib Ther. 2021;4(4):222-227. Published 2021 Oct 15. [Content Brief]
[4]. Wu ZL, et al. Receptor tyrosine kinase-like orphan receptor 1: A novel antitumor target in gastrointestinal cancers. World J Clin Oncol. 2024;15(5):603-613. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
huXBR1-402 Related Classifications
HY-P992376 Related Classifications
Powered by Bioz